Moderna (MRNA) Stock Surges 9% Following Positive FDA Review of mRNA Flu Vaccine

Key Takeaways

Table of Contents

Shares of Moderna rallied up to 9.1% following FDA briefing documents that revealed no “major deficiencies” in the mFlusiva mRNA influenza vaccine application
The Vaccines and Related Biological Products Advisory Committee (VRBPAC) will convene June 18 to assess whether mFlusiva’s benefits justify its risks for individuals aged 50 and above
Upon approval, mFlusiva would represent the United States’ inaugural mRNA-based seasonal influenza vaccine, with final FDA authorization anticipated by August 5
The biotech company pursues standard approval for the 50–64 age bracket and accelerated approval for those 65 and older
Concurrently, Moderna revealed organizational changes, appointing Ester Banque as Chief Commercial Officer in preparation for three potential product launches between 2027–2028

Shares of Moderna (MRNA) experienced a significant uptick Tuesday, climbing as high as 9.1% after FDA staff reviewers released briefing materials indicating that data supporting mFlusiva’s effectiveness in adults 65 and older appears adequate. The stock reached $56.12, approaching its 52-week peak of $57.80.

Moderna, Inc., MRNA

These documents surfaced in advance of Thursday’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) session, during which members will determine whether mFlusiva’s advantages outweigh potential risks for adults 50 years of age and older.

Most importantly, FDA staff identified no “major deficiencies” in the submission—the positive signal market participants had been anticipating.

The approval journey hasn’t been smooth. Last February, the FDA delivered a “refuse-to-file” notice, expressing concerns regarding trial methodology, particularly that the control group for seniors 65 and up received standard-dose flu vaccines instead of the higher-dose formulation recommended by the CDC for this demographic. The agency reversed its position shortly after Moderna consented to modify its submission.

This regulatory uncertainty created market volatility. Tuesday’s briefing materials signaled a distinctly more optimistic outlook.

Jefferies analyst Andrew Tsai characterized the evaluation as positive, forecasting $750 million in combined U.S. influenza and COVID-flu combination vaccine revenue by 2030.

FDA Staff Review: Key Findings

FDA evaluators observed that mFlusiva demonstrated superior relative vaccine efficacy compared to standard-dose flu vaccines in the 50 to 64 age demographic. For individuals 65 and older, the submission relies on immunogenicity metrics rather than direct efficacy comparisons against high-dose alternatives.

Reviewers identified certain constraints. The vaccine has undergone testing during only a single flu season, and immunocompromised individuals along with extremely frail elderly participants were not included in trials, creating uncertainty regarding effectiveness in these vulnerable populations.

Moderna has committed to conducting supplementary research and providing additional data for the 65-plus demographic should it obtain accelerated approval for that population segment.

The pharmaceutical company seeks standard approval for individuals aged 50 to 64 and accelerated approval for those 65 and above. Final FDA determination is scheduled for August 5.

If authorized, mFlusiva would become the first mRNA-technology seasonal influenza vaccine available in America.

Leadership Transformation Precedes Product Pipeline Expansion

Simultaneously, Moderna unveiled an internal restructuring initiative. The company designated Ester Banque as Chief Commercial Officer, a strategic appointment designed to position the organization for up to three product introductions—including a flu/COVID combination vaccine and a norovirus vaccine—slated for 2027 and 2028.

The confluence of improved regulatory prospects and a defined commercial strategy provided sufficient momentum to drive shares upward.

Moderna has gained 81.8% year-to-date. Nevertheless, despite this impressive run, investors who allocated $1,000 to MRNA five years ago would currently hold just $283.65.

The VRBPAC voting session is set for June 18.

✨ Limited Time Offer